naa a22 4500 510735541 CHVBK 20180411083008.0 cr unu---uuuuu 180411e20131201xx s 000 0 eng 10.1007/s11904-013-0186-4 doi (NATIONALLICENCE)springer-10.1007/s11904-013-0186-4 Treatment of Genotype 2 and Genotype 3 Hepatitis C Virus (HCV) Infection in Human Immunodeficiency Virus Positive Patients [Elektronische Daten] [Kristen Brown, Martin LaBrie, Carla Coffin] Approximately 25% of persons living with the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV). In cohort studies of HIV-HCV coinfection, HCV genotypes 2 and 3 account for 15%-64% of disease. Compared with HCV monoinfection, liver disease is accelerated in coinfected patients, and anti-HCV treatment is less successful. This article reviews the current knowledge and recommendations for management of HCV genotype 2 and 3 infection in patients living with HIV. While pegylated interferon (PEG-IFN)/ ribavirin (RBV) remains the standard treatment for HCV genotype 2/3 infection, ongoing clinical trials with more effective therapies will soon be available. In particular, an IFN sparing regimen of sofosbuvir/RBV may become available in 2014. It is also evident that HCV genotypes 2 and 3 respond differently to therapy and should be approached differently both in practice and in clinical trials. Issues including drug-drug interactions between anti-HCV and anti-HIV therapies are addressed. Springer Science+Business Media New York, 2013 HIV nationallicence HCV nationallicence Coinfection nationallicence HCV nationallicence Genotype 2 and genotype 3 nationallicence Pegylated-interferon (PEG-IFN) nationallicence Ribavirin (RBV) nationallicence Directly acting antiviral agents nationallicence Boceprevir nationallicence Telaprevir nationallicence Brown Kristen Department of Medicine, University of Calgary, Calgary, AB, Canada aut LaBrie Martin Foothills Medical Hospital, Alberta Health Services - Calgary Zone, Calgary, AB, Canada aut Coffin Carla Liver Unit, Division of Gastroenterology and Hepatology, Departments of Medicine and Microbiology, Immunology and Infectious Diseases, University of Calgary, 3280 Hospital Drive NW, T2N 1A4, Calgary, AB, Canada aut Current HIV/AIDS Reports Springer US; http://www.springer-ny.com 10/4(2013-12-01), 420-427 1548-3568 10:4<420 2013 10 11904 https://doi.org/10.1007/s11904-013-0186-4 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11904-013-0186-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brown Kristen Department of Medicine, University of Calgary, Calgary, AB, Canada aut NATIONALLICENCE 700 1- LaBrie Martin Foothills Medical Hospital, Alberta Health Services - Calgary Zone, Calgary, AB, Canada aut NATIONALLICENCE 700 1- Coffin Carla Liver Unit, Division of Gastroenterology and Hepatology, Departments of Medicine and Microbiology, Immunology and Infectious Diseases, University of Calgary, 3280 Hospital Drive NW, T2N 1A4, Calgary, AB, Canada aut NATIONALLICENCE 773 0- Current HIV/AIDS Reports Springer US; http://www.springer-ny.com 10/4(2013-12-01), 420-427 1548-3568 10:4<420 2013 10 11904 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer